Radiation Therapy + Atezolizumab for Small Cell Lung Cancer
Trial Summary
What is the purpose of this trial?
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy in addition to atezolizumab may extend the time without extensive small cell lung cancer growing or spreading compared to atezolizumab alone.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you are on immunosuppressive treatments or steroids above a certain dose, you may not be eligible. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the treatment Radiation Therapy + Atezolizumab for Small Cell Lung Cancer?
Research shows that adding atezolizumab to chemotherapy for extensive-stage small cell lung cancer (ES-SCLC) significantly improves survival outcomes compared to chemotherapy alone. Additionally, combining radiotherapy with immunotherapy like atezolizumab may enhance the body's immune response against tumors.12345
Is the combination of atezolizumab and radiation therapy safe for humans?
The combination of atezolizumab and radiation therapy has been studied in various trials and is generally well tolerated in humans. In a phase I trial for non-small cell lung cancer, the treatment was well tolerated, and the maximum tolerated dose of atezolizumab was established. Additionally, a study on bladder cancer also evaluated the safety of this combination, indicating it is safe for use in humans.13467
How is the treatment of radiation therapy combined with the drug atezolizumab unique for small cell lung cancer?
This treatment is unique because it combines atezolizumab, an immune checkpoint inhibitor that helps the immune system attack cancer cells, with radiation therapy, which may enhance the immune response against the tumor. This combination aims to improve outcomes for patients with small cell lung cancer by leveraging the potential synergistic effects of both therapies.34578
Research Team
Quynh-Nhu Nguyen
Principal Investigator
NRG Oncology
Eligibility Criteria
This trial is for adults with extensive stage small cell lung cancer who've had some success (partial response or stable disease) after initial treatment with chemotherapy and Atezolizumab. They should have a good performance status, controlled HIV if present, no more than three liver metastases, and adequate organ function. Pregnant women, those with severe other diseases or conditions that could affect the trial's outcomes are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive atezolizumab intravenously every 21 days, with or without radiation therapy for 5 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Atezolizumab
- Radiation Therapy
Atezolizumab is already approved in United States, European Union for the following indications:
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor
NRG Oncology
Collaborator